Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge.Investors Business Daily • 08/07/25
Eli Lilly's oral weight-loss pill didn't work so well, and the stock is plungingMarket Watch • 08/07/25
Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soarCNBC • 08/07/25
Eli Lilly's obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approvalCNBC • 08/07/25
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesityPRNewsWire • 08/07/25
These Stocks Are Moving the Most Today: Fortinet, AppLovin, Eli Lilly, Airbnb, Duolingo, and MoreBarrons • 08/07/25
GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli LillySeeking Alpha • 08/05/25
Eli Lilly Reverses Early Weakness, Closes Near Day's High After Key Trading SignalBenzinga • 08/05/25
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?Zacks Investment Research • 08/04/25
Insights Into Lilly (LLY) Q2: Wall Street Projections for Key MetricsZacks Investment Research • 08/04/25